CN119792555A - 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 - Google Patents

用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 Download PDF

Info

Publication number
CN119792555A
CN119792555A CN202510138513.7A CN202510138513A CN119792555A CN 119792555 A CN119792555 A CN 119792555A CN 202510138513 A CN202510138513 A CN 202510138513A CN 119792555 A CN119792555 A CN 119792555A
Authority
CN
China
Prior art keywords
paclitaxel
treatment
pharmaceutical composition
prodrug
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510138513.7A
Other languages
English (en)
Chinese (zh)
Inventor
G·墨斯科尼
D·贾贝斯
C·皮佐卡罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Farmaceutici SpA
Original Assignee
Fidia Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici SpA filed Critical Fidia Farmaceutici SpA
Publication of CN119792555A publication Critical patent/CN119792555A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202510138513.7A 2018-10-25 2019-10-23 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 Pending CN119792555A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT102018000009731 2018-10-25
IT102018000009731A IT201800009731A1 (it) 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
PCT/IB2019/059073 WO2020084525A1 (en) 2018-10-25 2019-10-23 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
CN201980064603.9A CN112805035A (zh) 2018-10-25 2019-10-23 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980064603.9A Division CN112805035A (zh) 2018-10-25 2019-10-23 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物

Publications (1)

Publication Number Publication Date
CN119792555A true CN119792555A (zh) 2025-04-11

Family

ID=65324453

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510138513.7A Pending CN119792555A (zh) 2018-10-25 2019-10-23 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物
CN201980064603.9A Pending CN112805035A (zh) 2018-10-25 2019-10-23 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980064603.9A Pending CN112805035A (zh) 2018-10-25 2019-10-23 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物

Country Status (21)

Country Link
US (4) US20200397909A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870233B1 (cg-RX-API-DMAC7.html)
JP (1) JP7518815B2 (cg-RX-API-DMAC7.html)
KR (1) KR102913965B1 (cg-RX-API-DMAC7.html)
CN (2) CN119792555A (cg-RX-API-DMAC7.html)
CA (1) CA3112188A1 (cg-RX-API-DMAC7.html)
DK (1) DK3870233T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190614A1 (cg-RX-API-DMAC7.html)
ES (1) ES2971217T3 (cg-RX-API-DMAC7.html)
FI (1) FI3870233T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240188T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066288T2 (cg-RX-API-DMAC7.html)
IT (1) IT201800009731A1 (cg-RX-API-DMAC7.html)
LT (1) LT3870233T (cg-RX-API-DMAC7.html)
MA (1) MA63879B1 (cg-RX-API-DMAC7.html)
PL (1) PL3870233T3 (cg-RX-API-DMAC7.html)
PT (1) PT3870233T (cg-RX-API-DMAC7.html)
RS (1) RS65193B1 (cg-RX-API-DMAC7.html)
SI (1) SI3870233T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400021T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020084525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000007747A1 (it) 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH666897A5 (fr) 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
IT1263393B (it) 1993-07-30 1996-08-05 Fidia Advanced Biopolymers Srl Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
IT1402385B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis
IT1402384B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium
EP3760707B1 (en) 2011-11-09 2025-11-19 Fibrobiologics, Inc. Fibroblasts for use in the treatment of degenerative disc disease
IT201600079633A1 (it) 2016-07-28 2018-01-28 Fidia Farm Spa Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico
CN110859962B (zh) 2019-11-25 2021-01-22 山东大学 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用

Also Published As

Publication number Publication date
PL3870233T3 (pl) 2024-05-06
US20210196833A1 (en) 2021-07-01
EP3870233B1 (en) 2023-12-06
KR20210083249A (ko) 2021-07-06
DK3870233T3 (da) 2024-02-05
US12465649B2 (en) 2025-11-11
CA3112188A1 (en) 2020-04-30
KR102913965B1 (ko) 2026-01-16
US20210268119A1 (en) 2021-09-02
FI3870233T3 (fi) 2024-02-07
JP2022503771A (ja) 2022-01-12
EA202190614A1 (ru) 2021-06-03
HRP20240188T1 (hr) 2024-05-10
HUE066288T2 (hu) 2024-07-28
RS65193B1 (sr) 2024-03-29
CN112805035A (zh) 2021-05-14
ES2971217T3 (es) 2024-06-04
US20240123077A1 (en) 2024-04-18
SI3870233T1 (sl) 2024-03-29
US20200397909A1 (en) 2020-12-24
MA63879B1 (fr) 2024-02-29
EP3870233A1 (en) 2021-09-01
SMT202400021T1 (it) 2024-03-13
IT201800009731A1 (it) 2020-04-25
LT3870233T (lt) 2024-02-26
JP7518815B2 (ja) 2024-07-18
WO2020084525A1 (en) 2020-04-30
PT3870233T (pt) 2024-02-01

Similar Documents

Publication Publication Date Title
Martin et al. Glycosidase activated prodrugs for targeted cancer therapy
Wang et al. Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies
ES2544481T3 (es) Taxanos unidos covalentemente a ácido hialurónico
CN101965201B (zh) 淋巴管内化疗药物载体
JP2005517048A (ja) シクロデキストリングラフト生体適合性両親媒性ポリマーおよびその製造および使用方法
US20240123077A1 (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
US20090324741A1 (en) Injectable polymer-lipid blend
WO2019210414A1 (en) Fucan-based compounds and complexes
US10478132B2 (en) Glucose conjugated gold nanoparticle
CN115667214A (zh) 包括药物二聚体的纳米颗粒及其用途
Park et al. Self-assembled nanocomplex of PEGylated protamine and heparin–suramin conjugate for accumulation at the tumor site
Lian et al. Rational design of hybrid nanomicelles integrating mucosal penetration and P-glycoprotein inhibition for efficient oral delivery of paclitaxel
Yu et al. Superior antitumor effect of self-assembly supramolecular paclitaxel nanoparticles
Liang et al. Acid-degradable magnolol-containing polymeric prodrug micelles for enhanced gastric cancer therapy
EA043782B1 (ru) Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря
HK40048954B (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
HK40048954A (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
JPWO2005037292A1 (ja) 糖鎖含有キトサン誘導体を含有する内視鏡手術用粘膜下膨隆液組成物
CN121891549A (zh) 一种基于紫杉醇衍生物的组合物及其制备方法和应用
Alvi Lysosomal targeting of a gelatin-doxorubicin conjugate and its evaluation for cell damage in two model breast cancer cell lines
Supasena Synthesis and characterization of polyethylene glycol-doxorubicin conjugates containing β-thiopropanamide linkers for enhanced selective cytotoxicity against breast cancer cells
박주호 Design and therapeutic evaluation of heparin based bioconjugate for oral delivery and antiangiogenic therapy
US20180251574A1 (en) Fucan-dendrimer based compounds and complexes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination